Kodyhua's spin-off plan approved, focusing on crop protection and seed business

K-LinePoet · 2026-03-01T13:08:18+00:00

Corteva plans to split into two independent publicly traded companies by 2025, focusing on crop protection and seed technology. The launch of biological seed treatments is expected in 2026, with projected operating profits of $4.18 billion. At the same time, in collaboration with Profluent Bio, they aim to accelerate the development of resistant and high-yield crops.

K-LinePoet

2026-03-01 13:08:18

Abstract generation in progress

Corteva (CTVA.US) has several important updates worth noting.

Company Project Progress

In October 2025, the Board of Directors approved splitting the company into two independent publicly traded companies, expected to be completed in the second half of 2026. After the split, “New Corteva” will focus on crop protection (including biopesticides), while “SpinCo” will focus on seeds and emerging technologies such as gene editing and biofuels.

Product Development Progress

The company plans to launch the biological seed treatment Lumidapt Valta LS in the U.S. market during the 2026 planting season. The product has completed regulatory approval stages and aims to increase crop yields.

Performance Outlook

Corteva provided a preliminary performance outlook for early 2026, with a projected median operating EBITDA of $4.18 billion, reflecting confidence in growth potential.

Strategic Initiatives

Corteva has entered into a multi-year partnership with Profluent Bio to accelerate the development of stress-resistant, high-yield crop varieties using AI technologies such as the OpenCRISPR-1 genome editor, which could drive long-term innovation.

This information is based on publicly available data and does not constitute investment advice.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.